THERAPY DOSSIER · th-4dd9e1bb7837

Corilagin, a natural polyphenol

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05206058 ↗Phase not recordedcompleted

To Exam the Effects of Phyllanthus Niruri Extracts (Corilagin, Phyllanthin and Brevifolin) on Human Neutrophils

Neutrophil · Phyllanthus Abnormis Poisoning

Enrolment: 240 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30630510 ↗2019Reported benefit

Corilagin alleviates acetaminophen-induced hepatotoxicity via enhancing the AMPK/GSK3beta-Nrf2 signaling pathway.

MouseChemical/toxinC57BL/6 wild-type and Nrf2 knockoutMaleIntraperitoneal15, 30 or 60 mg/kgPretreatment, with the final dose 1 h before acetaminophen challenge

Model: Acetaminophen-induced acute liver failure by single intraperitoneal injection, 900 mg/kg for survival endpoints and 400 mg/kg for tissue endpoints

Corilagin pretreatment reduced mortality and serum ALT and AST, limited necrosis, lowered myeloperoxidase and malondialdehyde and restored superoxide dismutase and the GSH to GSSG ratio, with protection largely abolished in Nrf2-deficient mice.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…